Utilizing breakthrough microcatheter technology, canaloplasty performed with the iTrack™ portfolio of canaloplasty devices (Nova Eye Medical, glaucoma-iTrack.com) is an implant-free, tissue-sparing MIGS procedure that achieves excellent clinical outcomes while also preserving the viability of future treatment options. Based on the same principles of angioplasty, canaloplasty combines viscodilation to enlarge Schlemm’s canal and to dilate the distal outflow system, with 360-degree catheterization of Schlemm’s canal to remove outflow resistance and improve outflow(1-3) – thereby reducing intraocular pressure by an average of 30%(4). It can also reduce the medication burden by an average of 50%(4).

For more information visit glaucoma-iTrack.com

IMPORTANT:
The (Nova Eye) iTrack™ Canaloplasty Microcatheter is
manufactured and distributed by Nova Eye, Inc.
The iTrack™ Canaloplasty Microcatheter is indicated for
fluid infusion or aspiration during surgery, and for catheterization
and viscodilation of Schlemm’s canal to reduce intraocular
pressure in adult patients with open angle glaucoma.
The iTrack™ Canaloplasty Microcatheter is not intended to
be used for catheterization and viscodilation of Schlemm’s
canal to reduce intraocular pressure in eyes of patients with
the following conditions: Neovascular glaucoma; Angle
closure glaucoma; and previous surgery with resultant
scarring of Schlemm’s canal.
For safety information, please visit glaucoma-iTrack.
com/us/safety

The canaloplasty ab-interno surgical technique, as
depicted in this video, is not an on-label indication for the
iTrack™ Canaloplasty Microcatheter in the USA.

• iTrack™, Canaloplasty for Glaucoma (Ab-Interno Surgical Technique) ( Download)